GlassScriptPhysician profile
Savannah Mae Sullivan
NPI 1124624671
$2,461.00
in general payments reported to CMS, 2019-2025
19 companies · $654 in 2025
The $654 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.55 · 2023: $601 · 2024: $1,109 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.97 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.39 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $240.74 | 2023-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $211.60 | 2023-2025 | Rexulti |
| Lundbeck LLC | $186.54 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Neos Therapeutics, LP | $113.93 | 2023-2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $102.41 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $84.20 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $82.36 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $69.71 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $69.69 | 2024 | |
| Janssen Pharmaceuticals, INC | $67.72 | 2024-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $31.78 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $23.86 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $23.52 | 2025 | Austedo Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22.37 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $19.92 | 2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $18.10 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.19 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savannah Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.